头孢唑肟治疗恶性血液病并发的重症感染24例

Ceftizoxime therapy in severe infectious complications of hematological malignancies in 24 patients

本文报道头孢唑肟(ceftizoxime)治疗24例(男14例,女10例,平均年龄46±16yr)恶性血液病并发重症感染。剂量为4-6g/d,iv,总剂量平均为41±16g,结果显效38％,有效25％;总有效率62％,头孢唑肟对革兰阳性菌和阴性菌均有效,但对绿脓杆菌感染无效。患者中性粒细胞绝对计数高于1.0×10~9/L的有效率高。本药副作用轻微,是一种安全,有效的广谐抗生素。

The therapeutic effect of ceftizoxime (CZX) in 24 patients (M14, F10, age 46±16yr) with hematological malignencies complicated by severe infections is reported. The daily dose of CZX was 4-6 g iv with an average total dosage of 41 ± 16g. Excellent response was noted in 38% and fair in 25%. The total response rate was 62%. CZX was effective for both gram positive and gram negative bacterial infection, but was of no use in all 3 cases of Pseudomonas aeruginosa infection. It was also found that the response of treatment was better for patients with neutrophil count above 1.0xl09/L than those below this level. Adverse effect was slight. Yellowish color vision was noted in* a patient, which disappeared after withdrawal of the drug. No fever or drug rash was noticed. It is suggested that CZX is a safe and useful broad-spectrum antibiotics for the treatment of severe infection complicating hematological malignancies.